^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    falbikitug (AZD0171)

    i
    Associations
    News

    Trials

    Company:
    AstraZeneca, Boehringer Ingelheim
    Drug class:
    LIF inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) (NCT05061550)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/14/2022
    Primary completion :
    05/09/2030
    Completion :
    05/09/2030
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan) • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)